Stay informed with this week’s cardiology roundup, featuring key advancements, clinical updates, and biopharma insights.
In Today’s Newsletter
Dive deeper
🧭 Philips DeviceGuide for heart valve repair [1] [17 Nov 2025]
Context: DeviceGuide layers AI device tracking onto EchoNavigator for structural heart procedures, tailored to mitral TEER.
Key point: Fuses live X-ray and echo to visualize device position and orientation in real time, supporting navigation in M-TEER.
Implication: Could streamline image-guided workflows and shorten learning curves, pending clinical adoption.
🫀 WINREVAIR hits Phase 2 CADENCE primary endpoint in CpcPH due to HFpEF [2] [US • 18 Nov 2025]
https://www.businesswire.com/news/home/20251118918484/en/
Context: Randomized, placebo-controlled proof-of-concept (n=164; 24 weeks) tested two WINREVAIR doses vs placebo.
Key point: Met primary endpoint with statistically significant, clinically meaningful PVR reduction vs placebo; safety aligned with known profile.
Implication: May influence prescriber choice and payer reviews pending full data.
🎵 Music therapy during PCI improves patient experience, signals hemodynamic benefit [3] [US • 19 Nov 2025]
Context: MUS.E I pilot RCT (n=100) at a Paris center, presented at TCT 2025, compared music before+during vs before-only vs none.
Key point: Music before+during PCI reduced post-procedure systolic BP and improved pain, HR, and troponin vs no music (endpoint specifics limited).
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🔎 Philips previews AI guidance for mitral TEER at PCR London Valves [4] [EU • 19 Nov 2025]
Context: DeviceGuide tracks mitral TEER devices and overlays a virtual 3D model onto live imaging.
Key point: Developed with Edwards Lifesciences, aims to standardize visual guidance and shorten learning curves.
Implication: Signals pipeline investment and modality expansion.
🤖 ESC Digital & AI Summit showcases detection and training tools [5] [EU • 21 Nov 2025]
Context: Berlin meeting (21–22 Nov) with 33 live presentations and awards.
Key point: Highlights include smartphone stethoscopes (Theodor Health), voice-based HF monitoring (Noah Labs), virtual CSP training (Epicardio), and PocDoc Healthy Heart Check.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🇵🇹 Portugal launches PULSAR study on diabetes and CV risk [6] [EU • 25 Nov 2025]
Context: SPD and SPC will survey ~25,000 adults across mainland and islands; pilot starts Dec 2025.
Key point: Updates decade-old prevalence data, incorporating modern thresholds and broader risk factors; first results before end-2026.
Implication: May expand screening, initiation, and follow-up at scale.
🧪 Tirzepatide bests dulaglutide on HF composite in SURPASS-CVOT analysis [7] [US • 25 Nov 2025]
Context: Event-driven RCT in T2D with ASCVD (n=13,299), doses up to 15 mg vs dulaglutide 1.5 mg weekly.
Key point: Lower all-cause death or HF events with tirzepatide (10.5% vs 12.1%; HR 0.86; 95% CI 0.77–0.95), including in those with prior HF.
Implication: May influence prescriber choice and payer reviews pending full data.
🧬 MDS associated with incident CVD in large database study [8] [10 Nov 2025]
Context: Observational analysis of ~1.14M individuals from DeSC database, mean follow-up 3.5 years.
Key point: MDS linked to higher risk of composite CVD (HR 1.86) and individual outcomes including AF (HR 2.26); consistent across subgroups.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🧷 Repatha RWE shows long-term MACE reduction vs non-treated cohorts [9] [US • 25 Nov 2025]
https://www.businesswire.com/news/home/20251125983606/en/
Context: REPATHA-CE, >110k ASCVD patients using Komodo data; presented at AHA 2025.
Key point: Repatha associated with 20% lower MI/stroke/revasc composite and 29% lower MI/stroke/CV-death composite at 4 years vs non-treated.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🏥 HRS/ACC roadmap for cardiac ablations in ASCs, aligned with new CMS coverage [10] [US • 25 Nov 2025]
Context: Scientific statement published in Heart Rhythm and JACC as CMS finalizes 2026 coverage for ASC-based EP ablations.
Key point: Recommends safety standards, patient selection, and workflows; cites real-world ASC outcomes comparable to HOPDs.
Implication: Introduces competition that may affect pricing and formulary access.
🧠 AI planning improves success and reduces waste in cardiovascular care [11] [26 Nov 2025]
Context: Systematic review of 11 RCTs in JACC Advances evaluated AI across echo, CT planning, and CT-FFR.
Key point: Examples include fewer non-obstructive angiographies with ML CT-FFR, higher complete LAA closure with AI CT planning, and faster, consistent LVEF reads.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
Why it matters
- AI layers in cath and structural labs are moving from promise to workflow impact, with signals of efficiency and consistency gains [1][4][11].
- Cardiometabolic agents continue to differentiate on HF composites, relevant for T2D with ASCVD and HF overlap [7].
- Real-world lipid lowering outcomes bolster long-term value arguments alongside legacy RCTs [9].
- Site-of-care shift for EP ablations may cut costs and waits if safety standards and regional capacity are protected [10].
- National surveillance like PULSAR can recalibrate prevention pathways and resource allocation [6].
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎬 Watch on YouTube. Subscribe and never miss a video.
🧰 See our full range of services. Discover how we can help you.
📚 See the full Cardiovascular archive on our research hub page.
FAQ
What is Philips DeviceGuide and where does it fit?
DeviceGuide is an AI device-tracking layer integrated with EchoNavigator to guide mitral TEER by fusing X-ray and echo into a single 3D view, previewed at PCR London Valves 2025 [1][4].
Did WINREVAIR show efficacy in CpcPH due to HFpEF?
Yes. In Phase 2 CADENCE, WINREVAIR met the primary endpoint with a significant PVR reduction vs placebo at 24 weeks, supporting Phase 3 planning, with safety consistent with prior profile [2].
How did tirzepatide perform vs dulaglutide on HF outcomes?
In SURPASS-CVOT, tirzepatide reduced all-cause death or HF events vs dulaglutide (HR 0.86), including in patients with baseline HF, while overall MACE was non-inferior (endpoint details as reported) [7].
What real-world benefit was seen with Repatha?
In >110k ASCVD patients, Repatha treatment was associated with lower 4-year composite MACE vs non-treated cohorts, aligning with FOURIER trial directionality (observational design) [9].
Can cardiac ablations be done safely in ASCs now?
HRS/ACC issued guidance for safe ASC ablations, coinciding with CMS adding EP ablations to the ASC covered list for 2026, noting comparable outcomes in emerging real-world data [10].
Is MDS a cardiovascular risk factor?
An observational study associated MDS with increased incident CVD, including IHD, stroke, HF, and AF, suggesting consideration as an independent risk factor in practice and policy [8].
Entities / Keywords
Philips DeviceGuide; EchoNavigator; mitral TEER; Edwards Lifesciences; Merck; WINREVAIR, sotatercept-csrk; CADENCE; HFpEF; CpcPH; MUS.E I; TCT 2025; ESC Digital & AI Summit; Theodor Health; Epicardio Virtual CSP; Noah Labs Vox; PocDoc Healthy Heart Check; PULSAR Portugal; SPD; SPC; tirzepatide; dulaglutide; SURPASS-CVOT; evolocumab; Repatha; Target RWE; AHA 2025; HRS; ACC; CMS; ambulatory surgical centers; JACC Advances; AI CT-FFR; LAA closure planning; echocardiography LVEF..
References
- https://www.appliedradiology.com/articles/philips-unveils-ai-powered-deviceguide-to-assist-in-minimally-invasive-heart-valve-repair
- https://www.businesswire.com/news/home/20251118918484/en/
- https://cardiovascularnews.com/music-therapy-improves-patient-experience-during-pci-and-shows-promise-for-fine-tuning-cardiovascular-parameters/
- https://cardiovascularnews.com/philips-previews-ai-powered-guidance-system-for-mitral-teer-procedures/
- https://www.news-medical.net/news/20251121/Digital-and-AI-innovations-in-cardiology-take-center-stage-at-ESC-Digital-AI-Summit.aspx
- https://healthnews.pt/2025/11/25/portugal-lanca-maior-estudo-nacional-sobre-diabetes-e-risco-cardiovascular/
- https://www.hcplive.com/view/tirzepatide-bests-dulaglutide-in-cardiovascular-outcomes-in-hf-with-stephen-nicholls-md
- https://medicalxpress.com/news/2025-11-myelodysplastic-syndromes-incident-cardiovascular-disease.html
- https://www.businesswire.com/news/home/20251125983606/en/
- https://cardiovascularbusiness.com/topics/clinical/heart-rhythm/cardiology-groups-share-new-recommendations-performing-safe-effective-cardiac-ablations-ascs
- https://medicaldialogues.in/cardiology-ctvs/news/ai-driven-planning-improves-procedural-success-and-reduces-waste-in-cardiovascular-care-jacc-advances-study-finds-159435